Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as LNTH2403 Phase 1 dose
LNTH-2403 · 1 trial · 1 indication
Incidence of DLTs during the first 8 weeks (DLT evaluation window) after the first dose of LNTH-2403
Type, frequency, severity, timing, and relationship to LNTH-2403 of all Treatment-emergent adverse event, (TEAEs) and Serious adverse events, (SAEs)
Event-Free Survival (EFS) at 4 months
| Arm | Type | Description |
|---|---|---|
| Phase 1- Escalating doses of LNTH-2403 administered once every 8 weeks | EXPERIMENTAL | Phase 1 will evaluate escalating doses of LNTH-2403 administered once every 8 weeks, with the potential to explore other dosing schedules based on observed radiation dosimetry and PK parameters and safety and tolerability data. |
| Phase 2 will evaluate LNTH-2403 as a single agent at the recommended phase 2 dose | EXPERIMENTAL | Phase 2 will evaluate LNTH-2403 as a single agent in participants with R/R osteosarcoma at the recommended phase 2 dose (RP2D). |
| Name | Type | Description |
|---|---|---|
| LNTH2403 Phase 1 dose | DRUG | LNTH-2403 administered once every 8 weeks, with the potential to explore other dosing schedules based on observed radiation dosimetry and PK parameters and safety and tolerability data. |
| Phase 2; LNTH2403 a single agent recommended phase 2 dose (RP2D). | DRUG | Once the RP2D is selected, phase 2 will commence |
Inclusion Criteria: Participants must meet all the following criteria to be enrolled in the study 1. Histopathologic documented diagnosis of R/R osteosarcoma 2. Must have disease characterized by at least one of the following (Participants meeting only (b.), only (c.), or only (b. and c.) must be d...
LNTH-2403 is an investigational small molecule developed by Lantheus Holdings, Inc. for relapsed or refractory osteosarcoma, a bone cancer that has returned or stopped responding to prior treatment. It is being studied as a single agent and is currently in Phase 1 clinical development.
LNTH-2403 is being evaluated for the treatment of relapsed or refractory osteosarcoma in patients whose disease has returned or progressed after earlier therapy. It is an investigational agent and has not been established as a treatment option outside of clinical research.
LNTH-2403 targets LRRC15, a protein expressed in the tumor microenvironment. By binding LRRC15, the agent is designed to deliver its therapeutic effect to osteosarcoma tissue. LRRC15 is the molecular target named for this small molecule program.
LNTH-2403 is being developed by Lantheus Holdings, Inc., which trades on the Nasdaq under the ticker LNTH. The company is the sponsor of the clinical program evaluating the agent in relapsed or refractory osteosarcoma.
LNTH-2403 is in Phase 1 clinical development. It is an investigational drug and is not approved by the FDA. The Phase 1 program is currently recruiting participants and has not yet completed.
LNTH-2403 is being studied in the Lu-TARGO trial, registered as NCT07357519, titled 177Lu-TARGeted Osteosarcoma Therapy. The Phase 1 trial is recruiting in the United States and plans to enroll 55 participants aged 12 years and older with relapsed or refractory osteosarcoma.
Yes, LNTH-2403 and LNTH2403 refer to the same investigational agent. The alternate spelling appears in references to the Phase 1 dose and the Phase 2 single agent recommended phase 2 dose, or RP2D, of the Lantheus osteosarcoma program.